Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz, Gelclair, Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:MTPH
- CUSIP: N/A
- Web: www.midatechpharma.com/
- Market Cap: £49.92 million
- Outstanding Shares: 48,699,000
- 50 Day Moving Avg: GBX 106.96
- 200 Day Moving Avg: GBX 117.20
- 52 Week Range: GBX 100 - GBX 189.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £6.92 million
- Price / Sales: 7.21
- Book Value: GBX 0.94 per share
- Price / Book: 1.09
- EBIDTA: ($14,820,000.00)
- Net Margins: -383.24%
- Return on Equity: -55.17%
- Return on Assets: -42.10%
- Average Volume: 28,432 shs.
Frequently Asked Questions for Midatech Pharma PLC (LON:MTPH)
What is Midatech Pharma PLC's stock symbol?
Midatech Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "MTPH."
Where is Midatech Pharma PLC's stock going? Where will Midatech Pharma PLC's stock price be in 2017?
2 brokerages have issued 1 year price targets for Midatech Pharma PLC's stock. Their predictions range from GBX 140 to GBX 297. On average, they expect Midatech Pharma PLC's stock price to reach GBX 218.50 in the next twelve months. View Analyst Ratings for Midatech Pharma PLC.
Who are some of Midatech Pharma PLC's key competitors?
Some companies that are related to Midatech Pharma PLC include Lipocine (LPCN), Zafgen (ZFGN), Ophthotech Corporation (OPHT), Galmed Pharmaceuticals (GLMD), Dicerna Pharmaceuticals (DRNA), Applied Genetic Technologies Corp (AGTC), Proteostasis Therapeutics (PTI), Nexvet Biopharma PLC (NVET), Ergomed PLC (ERGO), ImmuPharma PLC (IMM), ProNAi Therapeutics (SRRA), Intec Pharma (NTEC), Flex Pharma (FLKS), Leap Therapeutics (LPTX), Endocyte (ECYT), Synthetic Biologics (SYN), Verona Pharma Plc (VRP) and Xenon Pharmaceuticals (XENE).
Who are Midatech Pharma PLC's key executives?
Midatech Pharma PLC's management team includes the folowing people:
- James Neil Phillips, Chief Executive Officer, Director
- Nicholas John Robbins-Cherry, Finance Director, Director
- Craig Cook, Chief Operating Officer / Chief Medical Officer
- Daniel David Palmer Ph.D., Chief Scientific Officer
- Justin Barry, Head - Manufacturing
- Tim Sparey, Chief Business Officer
- Rolf Stahel, Non-Executive Chairman of the Board
- Simon De Vries, Non-Executive Director
- John Joseph Johnston, Non-Executive Director
- Michele Luzi, Non-Executive Director
How do I buy Midatech Pharma PLC stock?
Shares of Midatech Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Midatech Pharma PLC's stock price today?
MarketBeat Community Rating for Midatech Pharma PLC (LON MTPH)MarketBeat's community ratings are surveys of what our community members think about Midatech Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Midatech Pharma PLC stock can currently be purchased for approximately GBX 102.50.
Consensus Ratings for Midatech Pharma PLC (LON:MTPH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 218.50|
Analysts' Ratings History for Midatech Pharma PLC (LON:MTPH)
(Data available from 7/25/2015 forward)
|5/22/2017||N+1 Singer||Reiterated Rating||Buy||GBX 140|
|5/22/2017||Panmure Gordon||Reiterated Rating||Buy||GBX 297|
Earnings History for Midatech Pharma PLC (LON:MTPH)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Midatech Pharma PLC (LON:MTPH)
Current Year EPS Consensus Estimate: $-40.40 EPS
Dividend History for Midatech Pharma PLC (LON:MTPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Midatech Pharma PLC (LON:MTPH)Insider Trades by Quarter for Midatech Pharma PLC (LON:MTPH)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/18/2015||Phillips,James Neil||Insider||Buy||960||GBX 204||£1,958.40|
|6/26/2015||Phillips,James Neil||Insider||Buy||2,572||GBX 3.09||GBX 7,947.48|
|6/24/2015||Phillips,James Neil||Insider||Buy||2,000||GBX 2.87||GBX 5,740|
|6/23/2015||Robbins-Cherry,Nicholas||Insider||Buy||500||GBX 2.88||GBX 1,440|
Headline Trends for Midatech Pharma PLC (LON:MTPH)
Latest Headlines for Midatech Pharma PLC (LON:MTPH)
Midatech Pharma PLC (MTPH) Chart for Tuesday, July, 25, 2017